The A-List: 2005's Trend-Shaping Series A Financings
This article was originally published in Start Up
2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.
You may also be interested in...
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
There’s still money for early-stage innovation despite worries to the contrary, but total dollars for Series A financings remain about one-third fewer than during the high years of the mid-2000s, and investor syndicates are mindful of making those dollars stretch as far as possible. For the 2012 A-List, our ninth, we’ve decided to ask a fundamental question as the life science venture world goes through economic upheaval: does “Series A” mean the same thing, or conjure the same connotations, as it did when the class of 2004 made the first A-List?